Hospital Acquired Bacterial Infections Market to 2017

NEW YORK , Jan. 3, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Hospital Acquired Bacterial Infections Market to 2017 – Niche Players are Most Active in RD, Positioning Them as Potential Acquisition Targets for Big Pharma

http://www.reportlinker.com/p0748744/Hospital-Acquired-Bacterial-Infections-Market-to-2017—Niche-Players-are-Most-Active-in-RD-Positioning-Them-as-Potential-Acquisition-Targets-for-Big-Pharma.html#utm_source=prnewswireutm_medium=prutm_campaign=Pathology

Hospital Acquired Bacterial Infections Market to 2017 – Niche Players are Most Active in RD, Positioning Them as Potential Acquisition Targets for Big Pharma

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Hospital Acquired Bacterial Infections Market to 2017 – Niche Players are Most Active in RD, Positioning Them as Potential Acquisition Targets for Big Pharma”. The report provides in-depth analysis of drivers and barriers that impact the global Hospital Acquired Bacterial Infections (HABI) market. The report analyzes the markets for hospital acquired bacterial infections in the US, the top five countries in Europe (the UK, Germany , France , Italy and Spain ) and Japan . Treatment usage patterns, sales, prices are forecast until 2017 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The global hospital acquired bacterial infections market mainly comprises of four indications which are Urinary Tract Infections (UTI), pneumonia, Bloodstream Infections (BSI) and Surgical Site Infections (SSI). The total market of HABI is dependent on the major infections which are mainly caused by multi-drug resistant bacteria. Increasing human resistance to anti-bacterials leads to a need for advanced therapies to treat bacterial infections. Patent expiry of major antibacterials like Zyvox, Invanz, Tobi and Levaquin is set to erode the HABI market. This decline in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterial RD due to low Return on Investment (RoI). The lifespan of antibacterials is frequently limited due to the development of drug resistance. Big Pharma prefers acquiring small and niche pharmaceutical companies to widen their antibacterial pipeline portfolio.

The HABI market will show decline in the forecast period. The market is forecast to decline at a negative CAGR of 3.4% in the forecast period 2010–2017. Decline in the HABI market will be due to two main reasons. Firstly, there is resistance developed against antibacterials which makes existing antibacterials obsolete in some conditions. Secondly, there is an increase in hospital surveillance which leads to a decline in HABIs. Based on CDC data, 20% to 30% of hospital acquired infections can be prevented by infection control programs. There is formation of government bodies which are making it mandatory for hospitals to cut down on the spread of infections in the healthcare setup.

Scope

– Annualized market data for the HABI market from 2002 to 2010, forecast forward to 2017.

– Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.

– Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany , France , Italy , Spain and Japan .

– Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.

– Key drivers and barriers that have a significant impact on the market.

– Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, JJ, Cubist and other niche companies like Trius Therapeutics and Tetraphase Pharmaceuticals.

– Key MA activities, licensing agreements, that have taken place since 2004 in HABI market.

Reasons to buy

– Align your product portfolio to the markets with high growth potential.

– Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

– Develop key strategic initiatives by understanding the key focus areas of leading companies and niche companies which are helpful in extending pipeline portfolio.

– Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

List of Tables

1.1 List of Tables

Table 1: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2010 11

Table 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2010-2017 11

Table 3: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 13

Table 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 13

Table 5: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2002-2010 14

Table 6: Hospital Acquired Bacterial Infections Market, Global, Treatment Usage Patterns (million), 2010-2017 15

Table 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2010 18

Table 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2010-2017 18

Table 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 19

Table 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 20

Table 11: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2010 21

Table 12: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2010-2017 22

Table 13: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2010 23

Table 14: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2010-2017 24

Table 15: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2010 25

Table 16: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2010-2017 25

Table 17: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2010 26

Table 18: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2010-2017 26

Table 19: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2010 28

Table 20: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2010-2017 29

Table 21: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2002-2010 30

Table 22: Hospital Acquired Bacterial Pneumonia Market, Global, Geographical Segmentation ($m), 2010-2017 31

Table 23: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2010 32

Table 24: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2010-2017 32

Table 25: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 33

Table 26: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 33

Table 27: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010 35

Table 28: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017 36

Table 29: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2010 37

Table 30: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2010-2017 38

Table 31: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2010 39

Table 32: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2010-2017 40

Table 33: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2010 40

Table 34: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2010-2017 41

Table 35: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2002-2010 42

Table 36: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (thousand), 2010-2017 43

Table 37: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2010 44

Table 38: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2010-2017 45

Table 39: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2010 46

Table 40: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2010-2017 47

Table 41: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2010 48

Table 42: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2010-2017 48

Table 43: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2010 49

Table 44: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2010-2017 49

Table 45: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2010 50

Table 46: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2010-2017 51

Table 47: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Sales Value ($m), 2002-2010 52

Table 48: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Sales Value ($m), 2010-2017 52

Table 49: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Sales Value ($m), 2002-2010 53

Table 50: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Sales Value ($m), 2010-2017 53

Table 51: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Annual Cost of Therapy ($), 2002-2010 54

Table 52: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Annual Cost of Therapy ($), 2010-2017 54

Table 53: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Treatment Usage Pattern (thousand), 2002-2010 55

Table 54: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Treatment Usage Pattern (thousand), 2010-2017 55

Table 55: Hospital Acquired Bacterial Infections Market, Japan , Sales Value ($m), 2002-2010 57

Table 56: Hospital Acquired Bacterial Infections Market, Japan , Sales Value ($m), 2010-2017 57

Table 57: Hospital Acquired Bacterial Infections Market, Japan , Annual Cost of Therapy ($), 2002-2010 58

Table 58: Hospital Acquired Bacterial Infections Market, Japan , Annual Cost of Therapy ($), 2010-2017 58

Table 59: Hospital Acquired Bacterial Infections Market, Japan , Treatment Usage Pattern (thousand), 2002-2010 59

Table 60: Hospital Acquired Bacterial Infections Market, Japan , Treatment Usage Pattern (thousand), 2010-2017 60

Table 61: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase III, 2011 61

Table 62: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase II, 2011 62

Table 63: Hospital Acquired Bacterial Infections Market, Global, Key Pipeline Molecules, Phase I, Discovery, Pre-Clinical, 2011 63

Table 64: Hospital Acquired Bacterial Infections Market, Global, Major MA Deals, 2011 75

List of Figures

1.2 List of Figures

Figure 1: Hospital Acquired Bacterial Infections Market, Global, Drivers and Restraints, 2011 10

Figure 2: Hospital Acquired Bacterial Infections Market, Global, Sales Value ($m), 2002-2017 11

Figure 3: Hospital Acquired Bacterial Infections Market, Global, Revenue Segmentation, 2010, 2017 12

Figure 4: Hospital Acquired Bacterial Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 13

Figure 5: Hospital Acquired Bacterial Infections Market, Global, Therapeutic Usage Patterns (million), 2002-2017 14

Figure 6: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Sales Value ($m), 2002-2017 18

Figure 7: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 19

Figure 8: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Flow Algorithm 20

Figure 9: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Treatment Usage Patterns (million), 2002-2017 21

Figure 10: Hospital Acquired Bacterial Urinary Tract Infections Market, Global, Geographical Segmentation ($m), 2002-2017 23

Figure 11: Hospital Acquired Bacterial Pneumonia Market, Global, Sales Value ($m), 2002-2017 25

Figure 12: Hospital Acquired Bacterial Pneumonia Market, Global, Annual Cost of Therapy ($), 2002-2017 26

Figure 13: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Flow Algorithm 27

Figure 14: Hospital Acquired Bacterial Pneumonia Market, Global, Treatment Usage Patterns (thousand), 2002-2017 28

Figure 15: Hospital Acquired Bacterial Pneumonia Market, Global, Market Geographical Segmentation ($m), 2002-2017 30

Figure 16: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Sales Value ($m), 2002-2017 32

Figure 17: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 33

Figure 18: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Flow Algorithm 34

Figure 19: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Treatment Usage Patterns (million), 2002-2017 35

Figure 20: Hospital Acquired Bacterial Surgical Site Infections Market, Global, Geographical Segmentation ($m), 2002-2017 37

Figure 21: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Sales Value ($m), 2002-2017 39

Figure 22: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Annual Cost of Therapy ($), 2002-2017 40

Figure 23: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Flow Algorithm 41

Figure 24: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Treatment Usage Patterns (million), 2002-2017 42

Figure 25: Hospital Acquired Bacterial Bloodstream Infections Market, Global, Geographical Segmentation ($m), 2002-2017 44

Figure 26: Hospital Acquired Bacterial Infections Market, Global, Sales Value by Geography ($m), 2002-2017 46

Figure 27: Hospital Acquired Bacterial Infections Market, The US, Sales Value ($m), 2002-2017 48

Figure 28: Hospital Acquired Bacterial Infections Market, The US, Annual Cost of Therapy ($), 2002-2017 49

Figure 29: Hospital Acquired Bacterial Infections Market, The US, Treatment Usage Patterns (million), 2002-2017 50

Figure 30: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Sales Value ($m), 2002-2017 52

Figure 31: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Sales Value ($m), 2002-2017 53

Figure 32: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Annual Cost of Therapy ($), 2002-2017 54

Figure 33: Hospital Acquired Bacterial Infections Market, Top Five Countries in Europe , Treatment Usage Patterns (thousand), 2002-2017 55

Figure 34: Hospital Acquired Bacterial Infections Market, Japan , Sales Value ($m), 2002-2017 57

Figure 35: Hospital Acquired Bacterial Infections Market, Japan , Annual Cost of Therapy ($), 2002-2017 58

Figure 36: Hospital Acquired Bacterial Infections Market, Japan , Treatment Usage Pattern (thousand), 2002-2017 59

Figure 37: Hospital Acquired Bacterial Infections, Global, Pipeline by Phase (%), 2010 61

Figure 38: Hospital Acquired Bacterial Infections Market, Global, SWOT – Johnson Johnson, 2010 69

Figure 39: Hospital Acquired Bacterial Infections Market, Global, SWOT – Pfizer, 2010 70

Figure 40: Hospital Acquired Bacterial Infections Market, Global, SWOT – Cubist, 2010 71

Figure 41: Hospital Acquired Bacterial Infections Market, Global, SWOT – Bayer, 2010 72

Figure 42: Hospital Acquired Bacterial Infections Market, Global, MA Deals by Geography (%), 2004-2011 73

Figure 43: Hospital Acquired Bacterial Infections Market, Global, MA Deals by Value (%), 2004-2011 74

Figure 44: Hospital Acquired Bacterial Infections Market, Global, Major MA Deals by Deal Type (%), 2004-2011 75

Figure 45: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Geography (%), 2004-2011 76

Figure 46: Hospital Acquired Bacterial Infections Market, Global, Major Licensing Agreements By Value (%), 2004-2011 77

Figure 47: GBI Research Market Forecasting Model 84

Companies Mentioned

Johnson Johnson (JJ)

Pfizer

Cubist Pharmaceuticals

Bayer

Trius Therapeutics

Tetraphase Pharmaceuticals Inc.

To order this report:

Pathology Industry: Hospital Acquired Bacterial Infections Market to 2017 – Niche Players are Most Active in RD, Positioning Them as Potential Acquisition Targets for Big Pharma

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

Leave a Reply